#129: ACCP thrombosis guidelines on aspirin in primary prevention; EMA on aliskiren, aprotinin, and orlistat; homocysteine saga: is gene analysis the final chapter?; FDA advisors recommend approval of obesity drug Qnexa; guideline-recommended HF therapies
ACCP thrombosis guidelines on aspirin in primary prevention; EMA on aliskiren, aprotinin, and orlistat; homocysteine saga: is gene analysis the final chapter?; FDA advisors recommend approval of obesity drug Qnexa; guideline-recommended HF therapies
Source: Radio TheHeart.org - Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
More News: Alli | Aspirin | Cardiology | Eating Disorders & Weight Management | Genetics | Heart | Obesity | Tekturna | Thrombosis | Xenical